Guardian Asset Advisors LLC Purchases 67 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Guardian Asset Advisors LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 967 shares of the pharmaceutical company’s stock after buying an additional 67 shares during the period. Guardian Asset Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $431,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. United Services Automobile Association bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth $2,933,000. Lee Johnson Capital Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $721,000. SteelPeak Wealth LLC bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $10,059,000. Moody Lynn & Lieberson LLC grew its position in Vertex Pharmaceuticals by 1.4% in the 2nd quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock worth $25,856,000 after purchasing an additional 822 shares during the last quarter. Finally, New England Research & Management Inc. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter worth $472,000. 90.96% of the stock is owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Down 0.9%

Shares of VRTX stock opened at $422.63 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The company has a market capitalization of $108.36 billion, a P/E ratio of 30.21 and a beta of 0.43. The firm has a 50-day moving average price of $398.38 and a 200 day moving average price of $435.23.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same period last year, the firm posted ($12.83) EPS. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They issued a “market perform” rating on the stock. Cantor Fitzgerald decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Canaccord Genuity Group decreased their price target on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Evercore ISI decreased their price target on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. Finally, UBS Group set a $553.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $494.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.